Enliven Therapeutics, Inc.

ELVN

Held by 4 specialist biotech funds

High Convergence

Share on X

Fund Holdings

4 fund convergence

Baker Bros. Advisors OrbiMed Advisors Commodore Capital

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management2.2%Nov 14, 2024

SC 13G/ARA Capital Management5.2%Feb 27, 2023

SC 13G/A

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 271,406Value: $4.2M

## Signal Note: Baker Bros. Initiates Position in Enliven Therapeutics (ELVN) **Note: The reported position size of ~$4.18B on 271,406 shares appears to be a data error — likely reflecting an inflated per-share price or misreported share count, as ELVN's entire market cap is roughly $1.5-2B. The actual position is likely in the low-to-mid single-digit millions, consistent with an early-stage exploratory stake.** That said, any new Baker Bros. initiation in a clinical-stage name warrants attention given their concentrated, high-conviction style and deep oncology expertise. Enliven's lead asset, ELVN-001 (a next-gen BCR-ABL inhibitor targeting resistant CML, including the T315I compound mutation), is in Phase 1/2 with data readouts expected in

OrbiMed AdvisorsNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

PHVS4 funds TERN4 funds XENE4 funds ALKS3 funds ARGX3 funds CLDX3 funds CNTA3 funds CTMX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: OrbiMed Entry into Enliven Therapeutics OrbiMed's $122.6M initiating position in ELVN signals conviction in the company's pipeline, likely driven by ELV-304 (ELV-304, a selective estrogen receptor degrader for breast cancer) which entered Phase 2 in 2023 with clinical readouts expected in 2024-2025. The $122.6M position size—substantial for a micro-cap initiator—suggests OrbiMed sees value ahead of Phase 2 data maturation or potential partnership catalysts. This is a thesis bet on clinical validation rather than de-risking, given ELVN's pre-commercial stage.